Table 5.
Mean BPND valúes (± SD), estimates of Omax and IC50, and mean occupancy values in 10 representative regions whose mean baseline BPND values exceeded 0.5.
| BPND of [11C]DASB | Omax (%) | IC50 (ng/mL) | Mean occupancy | |
|---|---|---|---|---|
| Caudal anterior cingulate | 0.57 ± 0.15 | 85.1 | 8.25 | 74.2 ± 11.8 |
| Rostral anterior cingulate | 0.54 ± 0.13 < | 83.3 | 3.77 | 78.1 ± 10.4 |
| Insula | 0.71 ± 0.16 | 85.8 | 3.48 | 80.7 ± 8.1 |
| Posterior cingulate | 0.58 ± 0.18 | 60.3 | 0.02 | 60.3 ± 12.7 |
| Amygdala | 1.38 ± 0.30 | 97.4 | 5.01 | 89.4 ± 7.0 |
| Caudate nucleus | 1.00 ± 0.27 | 95.7 | 2.94 | 90.9 ± 10.1 |
| Putamen | 1.58 ± 0.25 | 75.4 | 2.08 | 72.7 ± 5.8 |
| Globus Pallidus | 1.48 ± 0.32 | 76.7 | 4.29 | 71.2 ± 6.8 |
| Ventral striatum | 1.78 ± 0.29 | 87.8 | 3.17 | 83.0 ± 5.5 |
| Thalamus | 1.4 ± 0.27 | 81.9 | 3.61 | 76.9 ± 4.8 |
Binding potential, BPND; maximal attainable occupancy, Omax; Half maximal inhibitory concentration, IC50. Sample size (n=16) LLD patients treated with Citalopram